Durability of mRNA-1273 protection against symptomatic COVID-19 examined
New retinal examination can predict a heart attack
13 June 2022Boosting the immune response against cancer
13 June 2022Durability of mRNA-1273 protection against symptomatic COVID-19 examined
For individuals who receive two doses of mRNA-1273 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, vaccine efficacy (VE) against symptomatic COVID-19 appears to peak at 120 days after the first dose, according to a research letter published online June 8 in JAMA Network Open.
